Maciej Bryl

SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

Charles M. Rudin, Stephen V. Liu, Ross A. Soo et al. · Journal of Clinical Oncology · 2023 · 92 citations · Full text

SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).

Charles M. Rudin, Stephen V. Liu, Shun Lü et al. · Journal of Clinical Oncology · 2022 · 73 citations

Lba8507 Background, Primary Results, Immunology +20

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid et al. · Journal of Thoracic Oncology · 2022 · 68 citations · Full text

Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations

Paweł Krawczyk, Dariusz M. Kowalski, Rodryg Ramlau et al. · Oncology Letters · 2017 · 64 citations · Full text

PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

Niels Reinmuth, Maciej Bryl, Igor Bondarenko et al. · BioDrugs · 2019 · 54 citations · Full text